A lyophilisate of treosulfan is described which possesses favourable characteristics in terms of a short reconstitution time and a high purity and stability and which is particularly useful in the treatment of cancer and for conditioning therapy before transplantation of bone marrow or blood stem cells.

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Methods, apparatus and software allowing a plurality of users to exchange and display information in real time or near real time regarding the resources each of them is viewing. This information is mapped graphically through the positioning and appearance of tokens representing other users relative to the resources currently displayed to each user.

Unsaturated fatty alcohol alkoxylates, processes for making them, and methods of using them are disclosed. In one aspect, a monounsaturated fatty alcohol alkoxylate is made by reducing a metathesis-derived monounsaturated alkyl ester, followed by alkoxylation of the resulting monounsaturated alcohol. Microscopy reveals that the monounsaturated alkoxylates have isotropic and lamellar phases over a wider range of actives levels compared with their saturated analogs. This attribute expands formulating latitude for many end-use applications. The unsaturated fatty alcohol alkoxylates are valuable in, for example, agricultural solvents, nonionic emulsifiers for agricultural compositions, hard surface cleaners, laundry detergents, specialty foams, additives or surfactants for paints or coatings, and surfactant compositions for enhanced oil recovery.

Unsaturated fatty alcohol alkoxylates, processes for making them, and methods of using them are disclosed. In one aspect, a monounsaturated fatty alcohol alkoxylate is made by reducing a metathesis-derived monounsaturated alkyl ester, followed by alkoxylation of the resulting monounsaturated alcohol. Microscopy reveals that the monounsaturated alkoxylates have isotropic and lamellar phases over a wider range of actives levels compared with their saturated analogs. This attribute expands formulating latitude for many end-use applications. The unsaturated fatty alcohol alkoxylates are valuable in, for example, agricultural solvents, nonionic emulsifiers for agricultural compositions, hard surface cleaners, laundry detergents, specialty foams, additives or surfactants for paints or coatings, and surfactant compositions for enhanced oil recovery.

The compositions and compounds of Formula I which includes a salt of duloxetine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of major depressive disorder, general anxiety disorder, urinary incontinence, painful peripheral neuropathy, diabetic neuropathy, fibromyalgia, and chronic musculoskeletal pain associated with osteoarthritis and chronic lower back pain.

Compounds of the formula (I), (Ia) or (Ib) wherein A.sub.1, and A.sup. is for example (II) is 1 or 2; X is C.sub.1-C.sub.4 alkylene or CO; Y is for example O, O(CO), O(CO)O, R.sub.1 is for example hydrogen, d-dsalkyl, C.sub.3-C.sub.30cycloalkyl, phenyl, naphthyl, anthracyl, phenanthryl, biphenylyl, fluorenyl or C.sub.3-C.sub.20heteroaryl, all of which optionally are substituted; R.sub.2 and R.sub.3 for example are C.sub.1-C.sub.10haloalkylene which is optionally substituted, or R.sub.2 and R.sub.3 are phenylene, which optionally is substituted; R.sub.4 is a group (A) or a group (B); R.sub.5 and R.sub.6 for example are C.sub.1-C.sub.20alkyl; or R.sub.4 and R.sub.5 or R.sub.4 and R.sub.6 together form a straight-chain C.sub.2-C.sub.6alkylene, R.sub.5 and R.sub.6 together form a straight-chain C.sub.2-C.sub.6alkylene; R.sub.7, R.sub.8, R.sub.9 and R.sub.10 ifor example are C.sub.1-C.sub.20alkyl; M for example is C.sub.1-C.sub.20alkylene, C.sub.2-C.sub.20alkenylene, C.sub.2-C.sub.20alkynylene; R.sub.25 and R.sub.26 are for example hydrogen, C.sub.1-C.sub.20alkyl; R.sub.27, R.sub.28, R.sub.29, R.sub.30 and R.sub.31 are for example hydrogen, C.sub.1-C.sub.20alkyl, C.sub.2-C.sub.20alkenyl, C.sub.3-C.sub.20cycloalkyl, or two radicals R.sub.27 and R.sub.28, R.sub.28 and R.sub.29, R.sub.29 and R.sub.30 and/or R.sub.30 and R.sub.31 together form a straight-chain C.sub.2-C.sub.6alkylene, or R.sub.25 and R.sub.27 together form 1,2-phenylene, R.sub.33 and R.sub.34 for example are hydrogen, C.sub.1-C.sub.20alkyl; R.sub.35, R.sub.36 and R.sub.37 for example are hydrogen, C.sub.1-C.sub.20alkyl; are suitable as thermo-acid generators. ##STR00001##

Compounds of the formula (I), (Ia) or (Ib) wherein A.sub.1, and A.sup. is for example (II) is 1 or 2; X is C.sub.1-C.sub.4 alkylene or CO; Y is for example O, O(CO), O(CO)O, R.sub.1 is for example hydrogen, d-dsalkyl, C.sub.3-C.sub.30cycloalkyl, phenyl, naphthyl, anthracyl, phenanthryl, biphenylyl, fluorenyl or C.sub.3-C.sub.20heteroaryl, all of which optionally are substituted; R.sub.2 and R.sub.3 for example are C.sub.1-C.sub.10haloalkylene which is optionally substituted, or R.sub.2 and R.sub.3 are phenylene, which optionally is substituted; R.sub.4 is a group (A) or a group (B); R.sub.5 and R.sub.6 for example are C.sub.1-C.sub.20alkyl; or R.sub.4 and R.sub.5 or R.sub.4 and R.sub.6 together form a straight-chain C.sub.2-C.sub.6alkylene, R.sub.5 and R.sub.6 together form a straight-chain C.sub.2-C.sub.6alkylene; R.sub.7, R.sub.8, R.sub.9 and R.sub.10 ifor example are C.sub.1-C.sub.20alkyl; M for example is C.sub.1-C.sub.20alkylene, C.sub.2-C.sub.20alkenylene, C.sub.2-C.sub.20alkynylene; R.sub.25 and R.sub.26 are for example hydrogen, C.sub.1-C.sub.20alkyl; R.sub.27, R.sub.28, R.sub.29, R.sub.30 and R.sub.31 are for example hydrogen, C.sub.1-C.sub.20alkyl, C.sub.2-C.sub.20alkenyl, C.sub.3-C.sub.20cycloalkyl, or two radicals R.sub.27 and R.sub.28, R.sub.28 and R.sub.29, R.sub.29 and R.sub.30 and/or R.sub.30 and R.sub.31 together form a straight-chain C.sub.2-C.sub.6alkylene, or R.sub.25 and R.sub.27 together form 1,2-phenylene, R.sub.33 and R.sub.34 for example are hydrogen, C.sub.1-C.sub.20alkyl; R.sub.35, R.sub.36 and R.sub.37 for example are hydrogen, C.sub.1-C.sub.20alkyl; are suitable as thermo-acid generators. ##STR00001##

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.